Pfizer And Sangamo Start Phase III Study For Hemophilia A Gene Therapy

Giroctocogene Fitelparvovec Sustains Factor VIII Levels With No Bleeds

 
• By Kevin Grogan
  
New York, July 19, 2016: Corporate lettering on the exterior of the Pfizer headquarters in Manhattan.
Pfizer hoping to lead hemophilia A gene therapy field • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Blood and Clotting

More from Therapeutic Category